The UK and US have announced a landmark bilateral deal that will preserve zero levies on UK pharmaceutical products entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on medicines through the NHS. This move ensures that tariffs on these key exports will stay at zero for a period of 36 months.
This development comes after earlier threats to significantly raise import taxes on patented drug imports, with potential rates discussed as high as 100%.
"This deal between the Britain strengthens the worldwide climate for cutting-edge drugs and brings much-needed equity to U.S.–U.K. medicine commerce," an announcement said.
Trade Importance
Medicines represent one of the UK's most significant goods shipped to the United States, which is clearly the largest buyer for large companies like GSK and AstraZeneca.
Trade data show that in the year to the end of the third quarter, the UK shipped medicines worth billions to the US. This figure accounted for nearly one-fifth of all goods exports in that span.
"This guarantee safeguards employment, boosts funding and paves the way for the UK to become a international leader for medical research," a government official commented.
Detailed British Pledges
The agreement includes several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. Previously, refunds were more than 20%.
Recent Tensions
The pact takes place against a long-running dispute between the sector and the UK government over spending levels and regulatory access.
These tensions were heightened by claims that American consumers were charged significantly more for the identical medicines than patients in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been halted or abandoned, while substantial funding commitments have been announced toward US facilities.
One official stated that the NHS must increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its total funding over the past decade.
